Actuate Therapeutics receives FDA IND clearance for oral elraglusib Phase 1/2 study

ACTUATE THERAPEUTICS, INC.

FDA cleared IND for Phase 1/2 study of oral elraglusib tablet in advanced solid tumors; initiation planned for 2H 2026.
Oral formulation aims to achieve higher exposure than IV; PK exposure correlated with improved OS in mPDAC Phase 2.
Elraglusib plus RAS inhibitor preclinical results expected mid-2026; combination potential in RAS-driven cancers.
Industry veteran Martin Huber, MD, appointed to Board; former President and CEO of Mersana Therapeutics.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.